Ana M Progovac1,2, Brian O Mullin2, Timothy B Creedon2, Alex McDowell3,4, Maria Jose Sanchez-Roman2,5, Laura A Hatfield4, Mark A Schuster6, Benjamin Lê Cook1,2. 1. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. 2. Health Equity Research Lab, Department of Psychiatry, Cambridge Health Alliance, Cambridge, Massachusetts. 3. PhD Program in Health Policy, Harvard University, Cambridge, Massachusetts. 4. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts. 5. Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC. 6. Kaiser Permanente School of Medicine, Pasadena, California.
Abstract
Purpose: This study examines trends in Medicare beneficiaries' mental health care use from 2009 to 2014 by gender minority and disability status. Methods: Using 2009 to 2014 Medicare claims, we modeled mental health care use (outpatient mental health care, inpatient mental health care, and psychotropic drugs) over time, adjusting for age and behavioral health diagnoses. We compared trends for gender minority beneficiaries (identified using diagnosis codes) to trends for a 5% random sample of other beneficiaries, stratified by original entitlement reason (age vs. disability). Results: Adjusted outpatient and inpatient mental health care use decreased and differences generally narrowed between gender minority and other beneficiaries over the study period. Among beneficiaries qualifying through disability, the gap in the number of outpatient and inpatient visits (among those with at least one visit in a given year) widened. Psychotropic drug use rose for all beneficiaries, but the proportion of gender minority beneficiaries in the aged cohort who had a psychotropic medication prescription rose faster than for other aged beneficiaries. Conclusions: Mental health care needs for Medicare beneficiaries may be met increasingly by using psychotropic medications rather than outpatient visits, and this pattern is more pronounced for identified gender minority (especially aged) beneficiaries. These trends may indicate a growing need for research and provider training in safe and effective psychotropic medication prescribing alongside gender-affirming treatments such as hormone therapy, especially for aged gender minority individuals who likely already experience polypharmacy.
Purpose: This study examines trends in Medicare beneficiaries' mental health care use from 2009 to 2014 by gender minority and disability status. Methods: Using 2009 to 2014 Medicare claims, we modeled mental health care use (outpatient mental health care, inpatient mental health care, and psychotropic drugs) over time, adjusting for age and behavioral health diagnoses. We compared trends for gender minority beneficiaries (identified using diagnosis codes) to trends for a 5% random sample of other beneficiaries, stratified by original entitlement reason (age vs. disability). Results: Adjusted outpatient and inpatient mental health care use decreased and differences generally narrowed between gender minority and other beneficiaries over the study period. Among beneficiaries qualifying through disability, the gap in the number of outpatient and inpatient visits (among those with at least one visit in a given year) widened. Psychotropic drug use rose for all beneficiaries, but the proportion of gender minority beneficiaries in the aged cohort who had a psychotropic medication prescription rose faster than for other aged beneficiaries. Conclusions: Mental health care needs for Medicare beneficiaries may be met increasingly by using psychotropic medications rather than outpatient visits, and this pattern is more pronounced for identified gender minority (especially aged) beneficiaries. These trends may indicate a growing need for research and provider training in safe and effective psychotropic medication prescribing alongside gender-affirming treatments such as hormone therapy, especially for aged gender minority individuals who likely already experience polypharmacy.
Authors: Thomas G McGuire; Margarita Alegria; Benjamin L Cook; Kenneth B Wells; Alan M Zaslavsky Journal: Health Serv Res Date: 2006-10 Impact factor: 3.402
Authors: Juno Obedin-Maliver; Elizabeth S Goldsmith; Leslie Stewart; William White; Eric Tran; Stephanie Brenman; Maggie Wells; David M Fetterman; Gabriel Garcia; Mitchell R Lunn Journal: JAMA Date: 2011-09-07 Impact factor: 56.272
Authors: Ana M Progovac; Brian O Mullin; Emilia Dunham; Sari L Reisner; Alex McDowell; Maria Jose Sanchez Roman; Mason Dunn; Cynthia J Telingator; Frederick Q Lu; Aaron Samuel Breslow; Marshall Forstein; Benjamin Lê Cook Journal: Am J Prev Med Date: 2020-03-07 Impact factor: 5.043
Authors: Kristen Nocka; Madeline C Montgomery; Ana Progovac; Carly E Guss; Philip A Chan; Julia Raifman Journal: J Adolesc Health Date: 2020-12-24 Impact factor: 5.012